← RedHill Biopharma Ltd. (RDHL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RedHill Biopharma Ltd. (RDHL)
Pharmaceutical Preparations · market cap $4M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
RedHill Biopharma Ltd. (RDHL) is a small pharmaceutical company with 35 employees and a market cap of approximately $41.4 million, trading at roughly $0.71 per share. The company operates a multi-asset pipeline spanning Phase 2 and Phase 3 trials across infectious disease, gastrointestinal conditions, and oncology, with opaganib as its lead asset in a Phase 3 COVID-19 trial. Critical financial data — including cash position, runway, and dilution history — is unavailable, creating significant opacity around the company's near-term viability.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABC294640 | Phase 2 | Cholangiocarcinoma |
| Opaganib | Phase 3 | COVID-19 |
| RHB-105 | Phase 3 | Helicobacter Pylori Infection |
| RHB-102 | Phase 3 | Gastroenteritis |
| BEKINDA | Phase 2 | Irritable Bowel Syndrome With Diarrhea |
| RHB-104 | Phase 3 | Crohn's Disease |
| RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) | Phase 3 | Crohn Disease |
| Upamostat | Phase 2 | SARS-CoV-2 |
Price & technical context
3-month
-42.2%
6-month
-36.0%
12-month
-79.5%
52-wk range
$0.48–$2.52
vs 50-day MA
-23.3%
vs 200-day MA
-46.1%
Realized vol
89.5%
Max drawdown
-96.1%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RDHL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.